This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Alhemo — Description, Dosage, Side Effects | PillsCard
OTC
Alhemo
15 mg/1,5 ml, Roztwór do wstrzykiwań we wstrzykiwaczu
INN: Concizumabum
Data updated: 2026-04-13
Available in:
🇨🇿🇩🇪🇬🇧🇫🇷🇵🇱🇵🇹🇸🇰🇺🇦
Form
Roztwór do wstrzykiwań we wstrzykiwaczu
Dosage
15 mg/1,5 ml
Route
podanie podskórne
Storage
—
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
About This Product
Manufacturer
Novo Nordisk A/S (Dania)
Composition
Concizumabum 15 mg
ATC Code
B02BX10
Source
URPL
11 DESCRIPTION Concizumab-mtci, is a humanized IgG4 monoclonal antibody produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells with an approximate molecular weight of 149 kDa. Alhemo (concizumab-mtci) injection is a clear to slightly opalescent, and colorless to slightly yellow solution that may contain translucent to white particles. Alhemo is supplied as a single-patient-use prefilled pen for subcutaneous injection. Each 1 mL of Alhemo single-patient-use prefilled pen (60 mg/1.5 mL) contains 40 mg active ingredient concizumab-mtci. Each 1 mL of Alhemo single-patient-use prefilled pen (150 mg/1.5 mL) contains 100 mg active ingredient concizumab-mtci. Each 1 mL of Alhemo single-patient-use prefilled pen (300 mg/3 mL) contains 100 mg active ingredient concizumab-mtci. Each 1 mL of Alhemo single-patient-use prefilled pen contains the following excipients: arginine hydrochloride (5.27 mg), histidine (5.12 mg), phenol (3.5 mg), polysorbate 80 (0.25 mg), sodium chloride (1.46 mg), sucrose (51.3 mg), and water for injection. Hydrochloric acid and sodium hydroxide may be added to adjust the pH to 6.0.